Type 2 Diabetes Mellitus (T2DM) is a polygenic disorder with complex inheritance patterns influenced by gene-environment and gene-gene interactions. Based on our previous observation that T2DM may result from disturbed protein-protein interactions affected through disrupting modular domain interactions, we designed an approach to identify disease candidates in the T2DM linked genomic regions based on domain interactions and subsequent network analysis. The quantification of the plausible candidates was done by assigning a score called weight value ranging from 0 to 1 based on the relevance of its interacting partners in T2DM and network motif analysis. Proteins with higher weight value are probable T2DM candidates and are termed as High Weight Element (HWEs). Disease associated genes and ones with literature base and pathway information related to T2DM were identified as HWEs in our analysis. Apart from picking up certain already known T2DM genes, this approach also captured proteins of unknown functions and several new candidates for T2DM worth further studies. The validation of our approach in zebrafish model in vivo has been initially conceptualized. Functional role of one of HWEs with unknown molecular function that has never shown to be associated with T2DM but identified by our approach as T2DM candidate was assessed and validated using zebrafish as a model. Whole-Mount In situ hybridization in zebrafish embryos suggested the expression of this gene in the brain of zebrafish. Hyperhomocysteinemia, a non-protein thiol amino acid is a biochemical factor associated with a multitude of complex diseases. However, till date there is no plausible explanation for a single amino acid's involvement in so many diseases. The majority of plasma homocysteine is protein cysteine bound. We hypothesized that; homocysteine might bind to accessible cysteine residues in target proteins, thereby modulating its structure and/or function. Very little information is available on the structural aspect of protein homocysteine interaction and most of which are available were based on candidate protein interaction gleaned from clinical association such as clotting etc. In this study, we have identified potential homocysteine interacting proteins based on structural informatics such as cysteine content, solvent accessibility of cysteine residues and dihedral strain energies and pKa of these cysteines. Our structural informatics analysis yielded vital clues that matched disease etiology and association that has encompassed past homocysteine based clinico-epidemiology research. Pathway mapping of the cysteine rich proteins revealed that proteins in the coagulation cascade, notch receptor mediated signaling, LDL endocytosis, programmed cell death and extracellular matrix proteins were significantly over represented with cysteine rich proteins and we believe that homocysteine has a high probability to bind to proteins in these pathways Further, we successfully validated our prediction parameters on the proteins that have already been experimentally shown to bind homocysteine and our structural analysis argues a plausible explanation for these prior reported protein interactions with homocysteine that could not be previously explained. This study provides a plausible explanation for the origin of multi-system disorder that is associated with hyperhomocystenemia.
Curriculum Vitae: Hypertension and associated cardiovascular diseases are alarmingly on rise in India. Understanding the genetic basis has been of foremost concern globally. Consequently, the genes of vascular homeostasis gained significance as the candidates in relation to hypertension. We investigated the association of the potential polymorphisms in the genes of blood pressure regulation with hypertension in a case-control study. The aldosterone synthase (CYP11B2) -344T/C, intron-2 conversion, K173R, C5160A; angiotensinogen (AGT) G-6A, T174M, M235T; and endothelial nitric oxide synthase (eNOS) -922A/G, -786T/C, 4B/4A, G894T polymorphisms were analyzed for causal effect of single variants, haplotypes and genotypes-combinations. Elevated plasma aldosterone levels (P=0.03) & aldosterone to renin ratio (-P<0.0001) and lower plasma renin activity & nitric oxide levels (P<0.01, respectively) were obtained in hypertensives. The -344T/C and K173R polymorphisms were in complete linkage disequilibrium with each other and the intron-2 conversion allele was in absolute association with the T allele. Genotypescombinations between the -344T/C and intron-2 conversion polymorphisms revealed that combinations with TC or CC genotypes inclined towards higher BMI in both the groups (P<0.05). The overall likelihood haplotype profile difference of AGT between the two groups was highly significant (P<0.001). Genotypescombinations of the three polymorphisms of AGT having 6 wild-type alleles versus the remaining resulted in significantly higher odds (P<0.001); further as the number of mutant alleles in a combination increased, the systolic, diastolic and mean blood pressure increased (P<0.05). With respect to eNOS, novel risk haplotypes for the four polymorphisms were obtained (P<0.01). In conclusion, single variant versus haplotypes provided encouraging findings, such as the interaction of the 174T-allele with the M235T and G-6A polymorphisms in combinations or haplotypes emerged significant. The three biomarkers associated with hypertension and correlated differentially with few single respective variants and its haplotypes/ combinations. Currently, clinical research organizations (CROs) utilize routine methodologies for drug studies. Newer approaches which integrate the power of RNAi, Microarrays and Proteomics will help in broadening the scope of these studies, thereby generating more accurate data on the drug validations. Human Genome Project resulted in a flood of sequence information on about more than 30,000 human genes, which is a shot in the arm for the Pharma industry for identifying novel targets for various diseases. This led to development of novel drug candidates, including siRNA. RNAi-based screens have provided new opportunities for the discovery and validation of novel therapeutic targets in areas such as cancer and infectious diseases. The process has become more gene expression centric, bringing to the fore-front the roles of mRNA, siRNA, miRNA and thereby the proteome too, in understanding the various disease processes and also the responses of drugs. Integrating all these technologies is a tool of choice for functional genomic studies, drug target discovery and mechanism of action studies. Another powerful role of the RNAi is the rapid and accurate diagnosis of various diseases, predominantly on cancers. The strategy of these novel approaches will be discussed.
